Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NKTR – Nektar Therapeutics

Nektar Therapeutics
NKTR
$0.6725
Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $125,154,944.00
EPSttm : -0.63
finviz dynamic chart for NKTR
Nektar Therapeutics
$0.6725
0.34%
$0.0023

Float Short %

5.94

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

0.04

EPS Last/This Y

-0.19

EPS This/Next Y

0.07

Price

0.67

Target Price

4.92

Analyst Recom

1.75

Performance Q

-21.64

Relative Volume

1.84

Beta

0.56

Ticker: NKTR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07NKTR0.60570.060.0751248
2025-05-08NKTR0.61280.060.0251529
2025-05-09NKTR0.59190.060.1951847
2025-05-12NKTR0.71430.060.0051729
2025-05-13NKTR0.70.060.0054178
2025-05-14NKTR0.71240.060.0455108
2025-05-15NKTR0.67290.060.0455082
2025-05-16NKTR0.68050.060.0055072
2025-05-19NKTR0.69070.050.0144423
2025-05-20NKTR0.680.050.0745123
2025-05-21NKTR0.63070.060.0046328
2025-05-22NKTR0.64410.050.5346822
2025-05-23NKTR0.64810.072.5248189
2025-05-27NKTR0.66850.090.3649095
2025-05-28NKTR0.69510.090.0749257
2025-05-29NKTR0.73010.0912.0749470
2025-05-30NKTR0.72180.110.1150077
2025-06-02NKTR0.79630.110.1050478
2025-06-03NKTR0.74990.110.0751762
2025-06-04NKTR0.73980.110.3852102
2025-06-05NKTR0.67440.120.0852251
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07NKTR0.611.3- -0.72
2025-05-08NKTR0.621.3- -0.72
2025-05-09NKTR0.591.3- -0.72
2025-05-12NKTR0.711.3- -0.72
2025-05-13NKTR0.71-2.3- -0.72
2025-05-14NKTR0.71-2.3- -0.72
2025-05-15NKTR0.68-2.3- -0.72
2025-05-16NKTR0.68-2.3- -0.73
2025-05-19NKTR0.69-6.9- -0.73
2025-05-20NKTR0.69-6.9- -0.73
2025-05-21NKTR0.63-6.9- -0.73
2025-05-22NKTR0.64-6.9- -0.73
2025-05-23NKTR0.65-6.9- -0.73
2025-05-27NKTR0.671.1- -0.77
2025-05-28NKTR0.701.1- -0.77
2025-05-29NKTR0.731.1- -0.77
2025-05-30NKTR0.721.1- -0.77
2025-06-02NKTR0.791.1- -0.77
2025-06-03NKTR0.751.1- -0.77
2025-06-04NKTR0.751.1- -0.77
2025-06-05NKTR0.671.1- -0.77
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07NKTR-4.38-8.024.54
2025-05-08NKTR-4.38-8.024.54
2025-05-09NKTR-4.38-8.024.54
2025-05-12NKTR-4.38-6.554.98
2025-05-13NKTR-4.38-6.554.98
2025-05-14NKTR-4.38-6.554.98
2025-05-15NKTR-4.38-6.554.98
2025-05-16NKTR-4.38-6.554.98
2025-05-19NKTR-4.38-10.784.98
2025-05-20NKTR-4.38-10.784.98
2025-05-21NKTR-3.97-10.784.98
2025-05-22NKTR-4.56-10.784.98
2025-05-23NKTR-4.56-10.784.98
2025-05-27NKTR-4.56-7.074.98
2025-05-28NKTR-4.60-7.075.94
2025-05-29NKTR-4.60-7.075.94
2025-05-30NKTR-4.60-7.075.94
2025-06-02NKTR-4.60-6.755.94
2025-06-03NKTR-4.60-6.755.94
2025-06-04NKTR-4.60-6.755.94
2025-06-05NKTR-4.60-6.755.94
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.22

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-4.6

Institutional Transactions

-6.75

Beta

0.56

Average Sales Estimate Current Quarter

10

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

31

Growth Score

29

Sentiment Score

39

Actual DrawDown %

97.5

Max Drawdown 5-Year %

-98.3

Target Price

4.92

P/E

Forward P/E

PEG

P/S

1.44

P/B

9.14

P/Free Cash Flow

EPS

-0.64

Average EPS Est. Cur. Y​

-0.77

EPS Next Y. (Est.)

-0.7

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-152.49

Relative Volume

1.84

Return on Equity vs Sector %

-992.4

Return on Equity vs Industry %

-974.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

Nektar Therapeutics
Sector: Healthcare
Industry: Biotechnology
Employees: 61
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading